Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 440
- Registration Number
- NCT00000885
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States
🇺🇸Boston Med Ctr, Boston, Massachusetts, United States
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 34
- Registration Number
- NCT00000891
- Locations
- 🇺🇸
Case Western Reserve Univ, Cleveland, Ohio, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
A Study of Disease Progression and Anti-HIV Treatments
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 210
- Registration Number
- NCT00001068
- Locations
- 🇺🇸
Emory Univ. Hemophilia Program Office, Atlanta, Georgia, United States
🇺🇸Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States
🇺🇸Univ. of Cincinnati CRS, Cincinnati, Ohio, United States
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 55
- Registration Number
- NCT00000872
- Locations
- 🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States
🇺🇸Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States
The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT00002371
- Locations
- 🇺🇸
Harbor UCLA Med Ctr, Torrance, California, United States
🇺🇸SUNY at Stony Brook / Division of Infectious Diseases, Stony Brook, New York, United States
🇨🇦Montreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada
The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00002376
- Locations
- 🇺🇸
Kaiser Foundation Hospital, San Francisco, California, United States
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Target Recruit Count
- 390
- Registration Number
- NCT00002416
- Locations
- 🇺🇸
Dr Robert Wallace, St. Petersburg, Florida, United States
🇺🇸North Shore Univ Hosp, Great Neck, New York, United States
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 300
- Registration Number
- NCT00005017
- Locations
- 🇺🇸
Jaime Hernandez, Research Triangle Park, North Carolina, United States
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 325
- Registration Number
- NCT00002436
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Boston City Hosp / FGH-1, Boston, Massachusetts, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Dupont Merck
- Target Recruit Count
- 60
- Registration Number
- NCT00002227
- Locations
- 🇺🇸
The Whitman Walker Clinic, Washington, District of Columbia, United States
🇺🇸Richard Elion, Washington, District of Columbia, United States
🇺🇸Montrose Clinic, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.